Singapore's ASLAN Licenses Gastric Cancer Compound From Array; Will Bring To POC And Find Partner

Singapore's ASLAN Pharmaceuticals Pte Ltd. has inked a licensing deal with Colorado-based Array BioPharma Inc. to develop Array's oral HER2/EGFR inhibitor ARRY-543, currently entering Phase II for solid tumors